Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
Orsini selected as the exclusive specialty pharmacy for WAINUA (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
Orsini Selected by BioMarin to Dispense ROCTAVIAN™, the First Gene Therapy for the Treatment of Severe Hemophilia A
Orsini selected as the exclusive specialty pharmacy for WAINUA (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Selected by Marinus Pharmaceuticals as the Exclusive Specialty Pharmacy Partner for ZTALMY®
Orsini Selected by Sarepta Therapeutics to Dispense ELEVIDYS (delandistrogene moxeparvovec-rokl), the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Orsini Specialty Pharmacy Selected by Glaukos® Corporation as a Specialty Distribution Partner for Photrexa® and Photrexa® Viscous
Orsini Specialty Pharmacy Selected by Sarepta Therapeutics as a Limited Distribution Partner for AMONDYS 45 (casimersen)
Orsini Specialty Pharmacy Selected by PTC Therapeutics as a Limited Distribution Partner for EMFLAZA® (deflazacort)